Plus Therapeutics(US:PSTV)2026-03-12 20:21Financial Performance - The net loss for the year ending December 31, 2025, was $22.4 million, or $(0.29) per basic share, compared to a net loss of $13.0 million, or $(1.95) per basic share, for the year ending December 31, 2024[7]. - The total operating loss for the year ending December 31, 2025, was $15.3 million, an increase from $14.7 million for the year ending December 31, 2024, primarily due to the expansion of the CNSide operations team[6]. - The net loss increased significantly to $22,386 million in 2025 from $12,978 million in 2024, reflecting an increase of approximately 72%[21]. - The company reported a net loss per share of $0.29 for 2025, an improvement from a net loss per share of $1.95 in 2024[21]. Revenue and Expenses - The company recognized $5.2 million in grant revenue for the year ending December 31, 2025, compared to $5.8 million for the year ending December 31, 2024[6]. - Grant revenue decreased to $5,213 million in 2025 from $5,824 million in 2024, representing a decline of approximately 10.5%[21]. - Total operating expenses remained relatively stable at $20,511 million in 2025 compared to $20,519 million in 2024, showing a slight decrease of 0.04%[21]. - The company incurred research and development expenses of $8,379 million in 2025, down from $10,580 million in 2024, a decrease of about 20.8%[21]. Cash Position - The cash and investments balance was $13.1 million on December 31, 2025, compared to $3.6 million on December 31, 2024, indicating a significant increase in liquidity[6]. - Cash and cash equivalents at the end of the period increased to $8,758 million in 2025 from $76 million in 2024, marking a substantial increase[23]. - Net cash used in operating activities rose to $20,775 million in 2025, compared to $10,554 million in 2024, indicating an increase of about 96%[23]. - Financing activities generated a net cash inflow of $30,311 million in 2025, compared to $6,187 million in 2024, representing an increase of approximately 388%[23]. Future Outlook - The company expects research and development expenditures to increase in 2026 due to costs associated with the ReSPECT-LM clinical trial and manufacturing scale-up for REYOBIQ[8]. - The company anticipates general and administrative expenditures to increase in 2026 as it expands the CNSide commercial operations team, aiming for breakeven by 2027[9]. - The company plans to expand U.S. commercial payer coverage to over 150 million covered lives and secure a Medicare coverage pathway[12]. - The company aims to achieve over 1,250 annualized test orders and launch additional CSF tumor characterization assays to expand the CNSide platform[12]. Shareholder Information - The weighted average number of shares outstanding for basic common stock increased significantly to 77,804,612 in 2025 from 6,640,251 in 2024[21]. - Interest income decreased to $116 million in 2025 from $273 million in 2024, reflecting a decline of approximately 57.5%[21].